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Background: Surveillance of recent HIV infections (RHI) using an avidity assay has
been implemented at Dutch sexual health centres (SHC) since 2014, but data on RHI
diagnosed at other test locations is lacking.
Setting: Implementation of the avidity assay in HIV treatment clinics for the purpose of
studying RHI among HIV patients tested at different test locations.
Methods: We retrospectively tested leftover specimens from newly diagnosed HIV
patients in care in 2013–2015 in Amsterdam. Avidity Index (AI) values ≤0.80 indicated
recent infection (acquired ≤6 months prior to diagnosis), and AI > 0.80 indicated
established infection (acquired >6 months prior to diagnosis). An algorithm for RHI was
applied to correct for false recency. Recency based on this algorithm was compared with
recency based on epidemiological data only. Multivariable logistic regression analysis was
used to identify factors associated with RHI among men who have sex with men (MSM).
Results: We tested 447 specimens with avidity; 72% from MSM. Proportions of
RHI were 20% among MSM and 10% among heterosexuals. SHC showed highest
proportions of RHI (27%), followed by GPs (15%), hospitals (5%), and other/unknown
locations (11%) (p< 0.001). Test location was the only factor associated with RHI among
MSM. A higher proportion of RHI was found based on epidemiological data compared
to avidity testing combined with the RHI algorithm.
Conclusion: SHC identify more RHI infections compared to other test locations, as
they serve high-risk populations and offer frequent HIV testing. Using avidity-testing
for surveillance purposes may help targeting prevention programs, but the assay lacks
robustness and its added value may decline with improved, repeat HIV testing and
data collection.
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INTRODUCTION
In January 2014, the National Institute for Public Health
and the Environment (RIVM) implemented a biomarker-
assay (Architect avidity) to distinguish recently acquired HIV
infections (≤6 months prior to diagnosis) from established
HIV infections (acquired >6 months prior to diagnosis) in
routine HIV surveillance at sexual health centers (SHCs) in the
Netherlands (1, 2). The goal of this enhanced surveillance is
to monitor trends in recent HIV infections (RHI) for planning
and evaluating local and national HIV prevention programs.
RHI, especially those in the acute phase, are associated with
higher viral loads and contribute disproportionately to HIV
transmission (3, 4). Therefore, delayed diagnosis and treatment
of individuals with RHI may have significant individual and
public health implications (5).
The Architect avidity assay is one of several assays that have
been developed to distinguish recently acquired from established
HIV infections (6, 7). Following the recommendations from the
European Center for Disease Prevention and Control (ECDC),
various European countries implemented a biomarker-assay of
which the most commonly used are the Less-sensitive/Detuned
Vitros, the BED CEIA (a capture enzyme immunoassay), the
avidity assay (Lag-Avidity EIA, Architect HIV ag/ab combo or
Bio-Rad avidity), and the INNO-LIA (p31 antigen immunoblot))
(8–13). These assays can be combined with clinical data
resulting in a testing algorithm (RITA: recent infection testing
algorithm). Differences in the performance of the assays vary
due to differences in the recency windows of the assays (13).
Furthermore, previous studies showed that avidity assays are
less affected by HIV-1 subtype variation when compared to the
BED immune assays, supporting the use of avidity assays for
RHI monitoring. Results from an independent evaluation of the
performance of five individual HIV incidence assays showed
that the Lag-Avidity assay had the lowest false recency rate
(14). The first results from the Dutch enhanced surveillance at
SHCs showed high proportions of RHI (30–40%) among men
who have sex with men (MSM) and proportions of 10–11% for
heterosexuals (1, 15). However, of all individuals entering HIV
care in the Netherlands, only 30% are diagnosed at SHC (16).
Therefore, a better understanding is needed on the number of
RHI among individuals diagnosed at other test locations, such
as general practices (GPs) and hospitals where 28%, respectively
27% of all new HIV cases are diagnosed. We conducted a
pilot study in the Amsterdam region to assess the feasibility
of implementing the avidity assay for RHI at HIV treatment
centers, where all newly diagnosed HIV patients from various
test locations in this region are registered and treated. For this
region, where 22% of all new HIV infections in the Netherlands
are diagnosed (16), we collected leftover specimens from newly
diagnosed patients in care in 7 treatment centers. The samples
were tested with the avidity assay and subsequently corrected for
false recency with the RITA algorithm of the ECDC, that includes
the clinical data of AIDS-defining illness, CD4 count, and viral
load (17).
Last, we compared the performance of this algorithm for
biomarker-assays with routinely collected epidemiological data
only that can be used as indicators for recent infection, such as
(1) the date of the last negative HIV test in the past 6 months,
(2) CD4 of ≥500 cells/mm3 at diagnosis as described by Le
Guillou et al. (18) reclassified as established infection in presence
of AIDS-defining illnesses or viral load (<400 copies/ml), and (3)
a combination of these two epidemiological indicators, to assess
the added value of the HIV avidity assay for surveillance purposes
in an era of improved HIV testing and more comprehensive
data collection.
METHODS
Specimen and Data Collection
In 2016–2017, residual plasma or serum specimens from
individuals newly diagnosed with HIV-1 between 2013 and
2015 from 7 HIV treatment centers in Amsterdam, were
retrospectively collected and tested with an avidity assay (7,
19). Eligibility criteria for inclusion were: >16 years of age
at diagnosis, and having a stored serum or plasma sample
(volume >200 µl) within 4 weeks after HIV diagnosis and before
ART treatment. Demographic and clinical data were retrieved
from the national ATHENA database maintained by Stichting
HIV Monitoring (SHM). The AIDS Therapy Evaluation in the
Netherlands (ATHENA) national observational HIV cohort (20)
was initiated in 1998 and captures clinical data from >98% of all
patients with diagnosed HIV infection who are in HIV care in the
Netherlands. The data collection is continuous, and the database
of the ATHENA cohort is updated twice a year. ATHENA is
an open cohort, as new participants continue to be enrolled
on entry into HIV care, following a positive HIV diagnosis.
For our study data are extracted from medical records from
the patients registered in Amsterdam. Variables included were
age, gender, mode of transmission, region of origin (Western
or non-Western), location of HIV diagnosis or referral (SHC,
GP, hospital or other/unknown location), presumed country of
infection, area of residence (Amsterdam or other/unknown) at
the time of entering HIV care, (self-reported) date of last HIV
negative test, CD4 count at diagnosis, viral load at diagnosis,
and presence of AIDS-defining illness at diagnosis (16). The
classification of “Western/non-Western” refers to the geographic
region of origin based on the patients’ country of birth. The
“Western” region includes western and central Europe, North
America, and the Australian/Pacific region. All other regions
were classified as “non-Western.”
Laboratory Procedures
Avidity testing was performed using a standardized operation
procedure (SOP) in a routine diagnostic laboratory. Procedures
for avidity testing have been described elsewhere (7, 19). In
short, specimens were tested with an anti-HIV avidity assay using
a 4th generation commercial enzyme immunoassay (EIA), the
Architect HIV Ag/Ab Combo (Abbott Diagnostics, Wiesbaden,
Germany). Cut-off values of the Avidity Index (AI) were: ≤0.80
for recent infection (acquired≤6 months prior to diagnosis), and
AI > 0.80 for established infection (acquired >6 months prior
to diagnosis). Each run included two quality controls (QCs): a
negative control (NC) and a (weakly) positive control (PC) with
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an AI just below the cut-off of 0.80. In case of either a positive
NC or a negative/gray-zone PC test results were rejected and the
whole run was repeated.
The ECDC RITA algorithm for newly diagnosed patients was
applied to minimize misclassification of established infections
as recent, e.g., reduce the false recent rate (FRR) in subsequent
steps: (1) reclassify RHI as established infection if the patient
has an AIDS-defining illness, (2) RHI reclassified as established
infection as CD4 count <200 cells/mm3, and (3) RHI reclassified
as established infection as viral load <400 copies/ml at HIV
diagnosis (17).
Statistical Methods
Chi-square tests were used to compare characteristics between
individuals with and without a RITA result (mostly due to lack
of available sample), and between individuals with a recent
and established HIV infection. Linear regression analysis was
performed to assess trends in proportions of RHI from 2013 to
2015. Univariable and multivariable logistic regression analyses
were used to identify factors associated with RHI for MSM only,
due to low numbers of RHI among heterosexuals. Variables
included in the univariable model were year of diagnosis, region
of origin, country of infection, area of residency, and test location.
The multivariable final model was obtained from backward
stepwise deletion based on the probability of likelihood-ratio
statistics using conditional parameter estimates. P-values under
0.05 were considered statistically significant.
Lastly, proportions of RHI after applying the RITA algorithm
were compared with proportions of RHI defined as (1) prior
negative HIV test result ≤6 months before diagnosis, (2) CD4
count ≥500 cells/mm3 (18), reclassified as established infection
in presence of AIDS-defining illnesses or viral load (<400
copies/ml) at HIV diagnosis, and (3) 1 & 2 combined, i.e., option
2 corrected for false established cases based on last negative test
result ≤6 months before diagnosis. Data were analyzed using
IBM-SPSS 21 (IBM SPSS Statistics for Windows, version 24, IBM
Corp., Armonk, N.Y., USA).
RESULTS
New HIV Diagnoses and Avidity Testing
Between 2013 and 2015, 692 newly diagnosed HIV patients in
the Amsterdam region were registered in the ATHENA database,
of whom the median age was 40 years (range 18–77 years)
(Table 1). MSM accounted for 73.6% of diagnoses, heterosexual
males for 11.6% and heterosexual females for 10.5%. Themajority
of HIV patients was diagnosed at a SHC (39.0%), followed by GPs
(27.5%) and hospitals (26.6%). A specimen for avidity testing was
available for 447 patients (64.6%) (Figure 1).
Characteristics of patients with and without an avidity test
result were similar regarding age, mode of transmission, country
of infection, area of residency, and test location. However,
patients with an avidity test result more often originated from
a non-Western region (40.5% vs. Western 29.0%, p < 0.01)
compared to patients without an avidity test result. Furthermore,
the proportion of patients with an avidity test result decreased
over time from 78 (2013), 68 (2014) to 49% (2015) (p < 0.001).
Proportions of Recent Infections
Characteristics according to proportions of RHI among MSM
and heterosexuals are displayed in Table 2. Of the 447 patients
with an avidity result, 86 (19.2%) patients had an avidity index
(AI) of ≤0.80; an indication for RHI. Data on CD4 count and
HIV viral load were available for 97.3 and 96.9% of patients with
an avidity test result. Applying the RITA algorithm, nine patients
were reclassified from recent to established HIV-infection based
on AIDS-defining illness (n= 1), CD4 count (n= 4), or viral load
(n= 4). This resulted in 77 patients (17.2%) classified as having a
RHI, with a false recent rate of 10.5% (Figure 1).
Patients with RHI, as defined by the RITA algorithm, were
younger, more often MSM, more likely to have acquired their
infection in the Netherlands, and were more often diagnosed
at a SHC compared to patients with an established HIV
infection (Table 1). Overall, proportions of RHI did not change
considerably over the study years (Supplementary Table 1).
Proportions of RHI at SHCs tended to be higher in 2015 (42.1%)
compared to 2013–2014 (24.2–22.5%, p = 0.09). Proportions of
RHI diagnosed at GPs fluctuated over the years (22.2, 6.7, 16.1%),
but numbers were small.
The proportion of MSM with a RHI was 20.4% (66/323)
compared to 9.6% (10/104) among heterosexuals. Proportions
of RHI among MSM were highest at SHCs (28.9%), followed
by GPs (15.4%), other/unknown test locations (16.7%), and
hospitals (6.8%, p < 0.001). Proportions of RHI among
heterosexuals were highest at GPs (16.2%, p = 0.39). For MSM
and heterosexuals, there was no significant difference in RHI
proportions between people of Western and non-Western origin
(Table 2).
Factors Associated With Recency
Univariable and multivariable analyses were performed to
identify factors associated with RHI among MSM (Table 2).
Univariable analyses showed lower odds of being diagnosed
with a RHI among MSM diagnosed at hospitals (OR: 0.18,
95% CI: 0.06–0.51), GPs (0.45, 0.23–0.88), or other/unknown
test locations (0.50, 0.11–2.35) compared to MSM diagnosed at
SHCs. MSM of older age, of Western origin, residing outside
Amsterdam, and who acquired their infection in the Netherlands
had slightly lower ORs for RHI, but not significantly. In the
multivariable model, only test location remained significantly
associated with diagnosis of RHI in MSM.
Comparison With Epidemiological Data
We compared proportions of RHI based on the RITA algorithm
to proportions of RHI based on three epidemiological measures
as described in the methods section: (1) prior negative HIV
test result ≤6 months before diagnosis, (2) CD4 count ≥500
cells/mm3 (10) combined with AIDS-defining illnesses and viral
load (<400 copies/ml) at HIV diagnosis, and (3) 1 & 2 combined.
Of 692 people included in our study, 446 (64%) had a reported
previous negative HIV test result in the ATHENA cohort. Of
those, 104 (23.3%) had a negative test result in the past 6
months (Table 3). A relatively high degree of misclassification
was observed if recent HIV test results (<6 months before HIV
diagnosis) were compared to RITA results. In total, 58 patients
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TABLE 1 | Characteristics of newly diagnosed HIV patients according to being RITA tested and to RITA result, region of Amsterdam, 2013–2015.
Total cohort RITA result
Total cohort
(n = 692) (%)
RITA tested
(n = 447) (%)
Not RITA
tested
(n = 289) (%)
p-value Recent
(n = 77) (%)
Non-recent
(n = 370) (%)
p-value
Year of diagnosis
2013 213 (30.8) 167 (37.4) 62 (21.5) <0.001 31 (40.3) 136 (36.8) 0.24
2014 232 (33.5) 158 (35.3) 84 (29.1) 21 (27.3) 137 (37.0)
2015 247 (35.7) 122 (27.3) 143 (49.5) 25 (32.5) 97 (26.2)
Age (years)
Median (IQR) 39 (18) 40 (17) 37 (20) 0.21 34 (58) 41 (53) 0.94
Age group
≤24 67 (9.7) 41 (9.2) 26 (10.6) 0.65 11 (14.3) 30 (8.1) 0.02
25–34 197 (28.5) 125 (28.0) 72 (29.4) 30 (39.0) 95 (25.7)
35–44 180 (26.0) 123 (27.5) 57 (23.3) 17 (22.1) 106 (28.6)
≥45 248 (35.8) 158 (35.3) 90 (36.7) 19 (24.7) 139 (37.6)
Mode of transmission
MSM 509 (73.6) 323 (72.3) 186 (75.9) 0.77 66 (85.7) 257 (69.5) 0.03
Heterosexual male 80 (11.6) 55 (12.3) 25 (10.2) 5 (6.5) 50 (13.5)
Heterosexual female 73 (10.5) 49 (11.0) 24 (9.8) 5 (6.5) 44 (11.9)
Unknown 30 (4.3) 20 (4.5) 10 (4.1) 1 (1.3) 19 (5.1)
Region of origin
Western 433 (62.6) 263 (58.8) 170 (69.4) 0.007 50 (64.9) 213 (57.6) 0.39
Non-Western 252 (36.4) 181 (40.5) 71 (29.0) 27 (35.1) 154 (41.6)
Unknown 7 (1.0) 3 (0.7) 4 (1.6) 0 (0.0) 3 (0.8)
Country of infection
Netherlands 352 (50.9) 231 (51.7) 121 (49.4) 0.56 48 (62.3) 183 (49.5) 0.04
Other/unknown 340 (49.1) 216 (48.3) 124 (50.6) 29 (37.7) 187 (50.5)
Area of residence
Amsterdam 531 (76.7) 338 (75.6) 193 (78.8) 0.35 61 (79.2) 277 (74.9) 0.42
Other/unknown 161 (23.3) 109 (24.4) 52 (21.2) 16 (20.8) 93 (25.1)
Test location
Sexual health center 270 (39.0) 175 (39.1) 95 (38.8) 0.39 48 (62.3) 127 (34.3) <0.001
General practice 184 (26.6) 115 (25.7) 69 (28.2) 20 (26.0) 110 (29.7)
Hospital 190 (27.5) 130 (29.1) 60 (24.5) 6 (7.8) 109 (29.5)
Other/unknown 48 (6.9) 27 (6.0) 21 (8.6) 3 (3.9) 24 (6.5)
with an available RITA test result had a recent negative HIV-test
prior to HIV-diagnosis. Of those 23/58 (39.7%) were correctly
classified as RHI, but 35/58 (60.3%) misclassified as established
HIV-infection with RITA. After correction for ‘false’ established
cases, the proportion of patients with RHI would rise from 19.2
to 25.1%.
Furthermore, proportions of RHI based on CD4 count (≥500
cells/mm3), a rough indicator for recency (18), were much higher
(34.7%) compared to proportions of RHI based on recent HIV
negative test (23.3%) or the RITA algorithm (17.2%). Correcting
false established cases based on CD4 count ≥500 cells/mm3 and
a recent HIV negative test, resulted in a higher concordance with
the RITA algorithm (n= 58), but also in more patients identified
as RHI (41.3%).
DISCUSSIONS
The proportions of recent HIV infections (RHI) based on
the algorithm for biomarker-assays (RITA) were 20.4% among
MSM and 9.6% among heterosexuals. SHC showed highest
proportions of RHI (27%), followed by GPs (15%), hospitals
(5%), and other/unknown locations (11%). In a multivariable
model amongMSM, test location was the only factor significantly
associated with RHI. A comparison between RITA outcomes
and recency based on routinely collected epidemiological data
showed discrepancies that suggest an underestimation of RHI
with the biomarker algorithm.
This is the first study to examine RHI at various test locations
in the Netherlands including SHCs, GPs and hospitals. The
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FIGURE 1 | Flowchart on HIV-patients included in the study, samples
collected, and samples tested with the Avidity Assay and numbers of recent
HIV-infections identified.
comprehensive data from the ATHENA cohort enabled us
to follow the RITA algorithm for RHI (17) and to compare
with other indicators for recency based on epidemiological
information, such as last negative HIV test results and
CD4 counts.
Our results on RHI illustrate that populations tested for HIV
at SHCs, GPs, and hospitals are different. HIV testing at GPs and
hospitals is more often associated with HIV indicator conditions,
while SHCs target high risk populations and offer repeat testing
(21). MSM in the Netherlands are advised to test for HIV at least
every 6 months (22), resulting in a higher proportion of RHI
among MSM at SHCs compared to heterosexuals and patients
tested at other locations. GPs contribute substantially to testing
and diagnoses of STIs (21), but to lesser extent for HIV (23, 24).
STI guidelines for GPs recommend to routinely test MSM and
persons with multiple sex partners for HIV (25), but previous
studies showed that low-threshold HIV testing among high-
risk populations is insufficient at GPs (23, 24). Information on
sexual identity is not registered, and both GP and patients may
be reluctant to discuss sexual risks at consultations (23, 26).
However, incorporating sexual preference in patient records may
contribute to broader test offers by GPs and earlier detection of
HIV among MSM. HIV indicator based testing is included in
GP guidelines and can reduce barriers to obtain sexual histories.
At hospitals, proportions of RHI are lowest (8%), and obviously
more associated with HIV indicator conditions (16, 23), but
also in this setting improvement of guideline uptake may be
warranted (27–29).
Comparison with international data on RHI infections is
hampered by the use of different RHI assays and window
phase variability, next to differences in study populations.
However, proportions of RHI among MSM and heterosexuals
were comparable to those of England, Northern Ireland and
Wales, who used a similar RITA algorithm with an avidity
test (AxSYM EIA) (2, 10, 30). They reported proportions of
RHI between 22 and 27% among MSM and 8–9% among
heterosexuals in 2009–2011 and 2015. In France, a different
assay (EIA-RI) was used in 2003–2008 with a proportion of RHI
of 25% among newly diagnosed individuals. The false recency
rate was not assessed with the ECDC algorithm but estimated
from two cohorts of patients (31). The proportion of RHI in
Ireland was considerably lower, 14% amongMSM and 8% among
heterosexuals, but a shorter window phase was described (4–
6 months), with a high proportion of diagnoses abroad (8).
Proportions of RHI were higher in European countries that used
the BED-immunoassay, with proportions of 35% among MSM
and 21% among heterosexuals in Germany (2008–2014) (9), 45
and 21% in Sweden (2003–2010) (12), and 31 and 15% in Spain
(2006-2008) (11).
High proportions of RHI among MSM are associated with
higher testing frequency and ongoing transmission. Repeat
testing among MSM has increased in the Netherlands over the
years (21), but there was no increasing trend in the proportion
of RHI. Likely, this is masked by a decline in HIV transmission
over the years in the MSM population or the 3 year study period
could be too short to show an increase. We also observed that
the proportion of RHI decreased with increasing age, which is
consistently reported by other European countries (9–12, 31).
Nonetheless, 15% of newly diagnosed MSM aged 45 years or
older in our study was recently infected, which indicates ongoing
HIV transmission in this age group. Although risk behavior can
be similar among older and younger adults, older adults may
perceive themselves at less risk for acquiring HIV and report
less use of preventive measures including condoms (32, 33).
Prevention to reduce risk behavior and to enhance test uptake
may also have an impact on MSM of older age. Furthermore,
efforts are needed to effectively increase HIV testing rates among
heterosexuals. HIV testing in the Netherlands concentrates on
heterosexuals originating from high endemic countries and more
than half of the heterosexuals included had a non-Western
background. RHI proportions were low among bothWestern and
non-Western individuals.
The Architect avidity has been described as an assay with a
relative high sensitivity and specificity compared to some other
incidence assays; it correctly classified recent HIV in 70% of cases
and correctly classified established HIV infection in 95% of cases
in a validation study by Hassan et al. (34). We compared the
performance of RITA with routinely collected data of last HIV
negative test results. It showed that the RITA classification is
not that robust and frequent mismatches were found when the
results were compared with data on negative HIV test results
in the 6 months prior to diagnosis. As testing history was not
available for everyone, we also compared the RITA classification
with a more complete variable but less specific indicator for RHI:
CD4 count ≥500 cells/mm3; which is considered the lower limit
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TABLE 2 | Proportions of recent HIV infections among heterosexuals and MSM, and associations of recent HIV infections among MSM by univariable and multivariable
logistic regression analysis, region of Amsterdam, 2013–2015.
Heterosexuals MSM
Recent infection Recent infection Univariate analysis Multivariate analysis
% (n/N) % (n/N) OR (95%CI) p-value OR (95%CI) p-value
Year of diagnosis
2013 11.4 (4/35) 21.3 (27/127) REF
2014 2.9 (1/34) 16.9 (20/118) 0.76 (0.40; 1.44) 0.39
2015 14.3 (5/35) 24.4 (19/78) 1.2 (0.61; 2.3) 0.61
Age group
≤24 28.6 (2/7) 26.5 (9/34) REF
25–34 11.1 (3/27) 28.0 (26/93) 1.08 (0.44; 2.62) 0.87
35–44 6.7 (2/30) 17.0 (15/88) 0.57 (0.22; 1.47) 0.24
≥45 7.5 (3/40) 14.8 (16/108) 0.48 (0.19; 1.22) 0.12
Region of origin1
Western 7.7 (3/39) 21.8 (46/221) REF
Non-Western 10.9 (7/64) 18.2 (20/110) 0.80 (0.44; 1.43) 0.45
Country of infection
Netherlands 12.8 (5/34) 23.6 (42/178) REF
Other/unknown 7.7 (5/60) 16.8 (24/143) 0.652 (0.37; 1.14) 0.13
Area of residency
Amsterdam 11.1 (8/72) 20.2 (52/257) REF
Other/unknown 6.3 (2/32) 21.9 (14/64) 1.15 (0.57; 2.17) 0.75
Test location
Sexual health center 8.3 (1/12) 28.9 (46/159) REF REF
General practice 16.2 (6/37) 15.4 (14/91) 0.45 (0.23; 0.88) 0.02 0.45 (0.23; 0.88) 0.02
Hospital 4.9 (2/41) 6.8 (4/59) 0.18 (0.06; 0.52) 0.002 0.18 (0.06; 0.51) 0.002
Other/unknown 7.1 (1/14) 16.7 (2/12) 0.50 (0.11; 2.35) 0.38 0.50 (0.11; 2.35) 0.37
1One heterosexual and two MSM with unknown region of origin, all non-recent HIV infections.
Missing values (Other/unknown) were included as category in the regression analysis in case of >5%.
TABLE 3 | Recent HIV infections based on routinely collected epidemiological data at HIV diagnosis (last negative test result and CD4 count) vs. RITA algorithm results.
RHI based on RITA algorithm
RHI Established infection Not RITA tested Total %RHI (unknown excluded)
RHI based on recent negative HIV test
RHI: ≤6 months before diagnosis 23 35 46 104 23.3
>6 months before diagnosis 41 190 111 342
Unknown 13 145 88 246
RHI based on CD4 count at diagnosis, FRR corrected1
RHI: CD4 >500 cells/mm3 47 111 69 227 34.7
CD4 ≤500 cells/mm3 29 248 150 427
Unknown 1 11 26 38
2, false established cases corrected with 1
RHI 58 125 89 272 41.3
Established infection 18 237 131 386
Unknown 1 8 25 34
Total 77 370 245 692
1False Recent Rate (FRR) corrected taking into account AIDS-defining illness and viral load (<400 copies/ml) at HIV diagnosis.
2Note in this comparison that a person with a negative test result >6 months before diagnosis may be still be recently infected. RITA, recent infection testing algorithm; RHI, recent HIV
infection.
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of the normal range in uninfected individuals. A French study
reported similar proportions of RHI (36%) based on CD4 count
≥500 cells/mm3 (18). It should be noted that CD4 counts vary
widely between individuals during disease progression, and may
drop to<500 cells/mm3 during acute infections and can be≥500
cells/mm3 up to several years after diagnosis (35), explaining the
higher proportion of RHI compared to the RITA classification. As
the RITA algorithm and alternative measurements lack precision,
the use of multi-assay algorithms (MAA) has been suggested, as
it significantly improves the prediction of HIV infection recency
(34). The validation study of Hassan et al. (34) showed with
regression analyses that the combination of the Architect avidity
and the INNO-LIA assay has the potential to identify a higher
proportion of recent HIV infections as, individually, the assays
have a predicted risk of being recent of 77 and 79%, respectively
but in combination the risk increases to 98% (34). However,
more research seems needed on costs and feasibility of these
combined approaches.
There are some other study limitations to report. First, only
patients from the Amsterdam region were included. Although
22% of all cases in the Netherlands are diagnosed in this region
(16), results may not be generalisable to other regions in the
Netherlands. HIV testing might be more common or accepted
in Amsterdam compared to other regions, possibly resulting in
higher rates of frequent testing and earlier detection of HIV.
Second, for only 65% of newly diagnosed patients stored samples
were available for avidity testing with a decreasing number of
samples available over time, especially for MSM and Western
individuals. Possibly, an earlier start of ART treatment in 2015
among Western individuals (27% in 2013 to 53% in 2015 within
a month after diagnosis) compared to non-Western individuals
(32–33%) could have resulted in a smaller availability of pre-ART
samples. As other characteristics were similar, we expect selection
bias to be limited.
In conclusion, although the use of the avidity assay for
surveillance purposes may help targeting prevention programs,
its robustness is limited and its added value, especially for the
MSM population, may decline over time with improved, repeat
HIV testing and data collection on testing history. Furthermore,
sample collection and logistics would be labor intensive and
costly when implemented in all 24 Dutch HIV treatment centers.
Therefore, routine incorporation of the avidity assay and the
RITA algorithm as part of the national surveillance at all HIV
treatment centers in the Netherlands seem neither feasible nor
useful in its current form. Instead of the avidity assay, taking
its limitations into account, future estimations of RHI could be
based on the date of last HIV negative test or in combination with
CD4 count and Western Blot patterns (for acute infections) and
may act as an alternative measure for HIV recency.
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